Drug intelligence / Profile preview

NEU-627

Development stage: Phase 1
Lead developer: Neuron23
Modality: Small Molecules
Administration: Oral

Overview

NEU-627 is a highly potent and selective central Tyrosine-protein kinase 2 (TYK2) inhibitor. It is a small molecule drug developed by Neuron23 for the treatment of neuroinflammatory diseases, with its primary indication being multiple sclerosis. The drug is designed to target TYK2 in the central nervous system and is currently in Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect in healthy volunteers[1][2][3][4]. Its mechanism of action involves inhibiting TYK2 activity to modulate immune responses implicated in neuroinflammation.

Other names: Neuron23-TYK2-Multiple SclerosisNeuron-23-TYK2-Multiple SclerosisNeuron 23-TYK2-Multiple Sclerosis

Targets

TYK2 (Tyrosine kinase 2)

Beyond the preview

Go deeper on NEU-627.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEU-627.

Explore the full profile